SCHEMBL13624293

SCHEMBL13624293

CC[C@@H](CNc1ccc(N2CCOCC2)cc1)NC(=O)[C@H](CC(C)C)N[C@@H](c1ccc2c(c1)OCO2)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 8/20 0.48
CTSK P43235 7/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
CTSS P25774 5/20 0.42
CTSB P07858 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 5/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GFER P55789 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624300 0.88 CTSL (0.51) CTSLCTSKCTSSCTSBALDH1A1
SCHEMBL4366149 0.88 CTSL (0.53) CTSLCTSKL3MBTL1CTSSCTSB
SCHEMBL13624298 0.87 CTSL (0.51) CTSLCTSKL3MBTL1CTSSCTSB
SCHEMBL13624299 0.85 CTSL (0.49) CTSLCTSKCTSSCTSBMAPT
SCHEMBL13624290 0.85 CTSK (0.51) CTSLCTSKCTSSCTSB
SCHEMBL13624295 0.84 CTSL (0.48) CTSLCTSKL3MBTL1CTSSCTSB
SCHEMBL13624307 0.84 CTSK (0.48) CTSLCTSKL3MBTL1CTSSCTSB
SCHEMBL13624297 0.84 CTSK (0.50) CTSLCTSKCTSSCTSB
SCHEMBL13624291 0.83 CTSL (0.50) CTSLCTSKL3MBTL1CTSSCTSB
SCHEMBL13624370 0.83 CTSL (0.49) CTSLCTSKL3MBTL1CTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS CTSE, SPINT2, CTSF CTSL 24/4885CTSK 15/4885L3MBTL1 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.